Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

BACKGROUND: The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety, and immunogenicity of atezolizumab in pediatric...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Shemesh, Colby S., Chanu, Pascal, Jamsen, Kris, Wada, Russ, Rossato, Gianluca, Donaldson, Francis, Garg, Amit, Winter, Helen, Ruppel, Jane, Wang, Xin, Bruno, Rene, Jin, Jin, Girish, Sandhya
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6868826/
https://ncbi.nlm.nih.gov/pubmed/31753029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0791-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados